Axcella says preclinical of AXA4010 data show multifactorial potential
Axcella Health announced mechanistic data for AXA4010 that are being presented today at the American Society of Hematology's Annual Meeting. Plasma amino profiles of adults with sickle cell disease were significantly different from adults in the control group, with a 50% reduction in Arginine and more than a 30% reduction in total essential amino acids, which include Leucine, Valine, Lysine, and Histidine, the company said in a statement. Endothelial cell cultures treated with TNFalpha and constituents of AXA4010 saw reduction in markers of vascular adhesion, inflammation and cell migration, it added. This was compared to cell cultures that were treated with glutamine and TNFalpha, which saw an increase in adhesion, no change in inflammation and a reduction in cell migration. Compared against individual amino acids, AXA4010 "constituents were better at improving overall RBC deformability by improving membrane flexibility, surface-to-volume ratio and intracellular viscosity," according to Axcella. "These data again demonstrate the potential of EMMs to impact multiple dysregulated metabolic pathways," said Bill Hinshaw, president and CEO of Axcella. "We are excited about the continued expansion of Axcella's portfolio beyond our liver- and muscle-related programs, into hematology."